While the financial impact is relatively modest for a company of DHG's scale, the incident reflects a broader trend of... Read more
Category: Uncategorized
BEYOND WEIGHT LOSS: WHY FRAILTY MONITORING MAY DEFINE THE NEXT ERA OF GLP-1 THERAPIES
The rapid expansion of GLP-1 receptor agonists has fundamentally reshaped obesity management, but a new study suggests that the next... Read more
CYLOSPORIASIS CASES SURGE IN THE U.S.: A PUBLIC HEALTH SIGNAL FOR FOOD SAFETY, DIAGNOSTICS, AND HEALTHCARE RESILIENCE
The United States is experiencing a significant increase in reported cyclosporiasis cases, a foodborne parasitic infection caused by Cyclospora cayetanensis.... Read more
HANOI TIGHTENS FOOD SAFETY ENFORCEMENT AS SCHOOL MEAL SUPPLY CHAINS COME UNDER SCRUTINY
Hanoi authorities have intensified oversight of school meal supply chains after inspections identified multiple violations involving food suppliers serving educational... Read more
FDA’S APPROVAL OF AT HOME LEQEMBI ADMINISTRATION COULD RESHAPE ALZHEIMER’S CARE DELIVERY
The U.S. Food and Drug Administration (FDA) has approved an at home starting dose option for Leqembi (lecanemab), allowing eligible... Read more
NOVO NORDISK ADVANCES ITS RARE DISEASE AMBITIONS WITH POSITIVE PHASE III HEMOPHILIA DATA
Novo Nordisk has announced positive results from the Phase III FRONTIER4 extension study, reinforcing the long term safety and efficacy... Read more
ASTRAZENECA’S LATEST LICENSING DEAL UNDERSCORES THE RISE OF CHINA AS A GLOBAL ONCOLOGY INNOVATION HUB
AstraZeneca has expanded its oncology pipeline through a new licensing agreement with Dizal Pharmaceutical, securing global rights outside mainland China... Read more
PRIVATE EQUITY IS RESHAPING INDIA’S SPECIALTY HEALTHCARE. MAXIVISION’S IPO PLANS SIGNAL WHAT COMES NEXT
India's healthcare investment landscape is entering a new phase as Maxivision Super Specialty Eye Hospitals, backed by private equity firm... Read more
GSK’S JEMPERLI SIGNALS A NEW ERA OF ORGAN PRESERVING CANCER CARE
GSK has reported encouraging Phase II clinical results for Jemperli (dostarlimab) in patients with locally advanced mismatch repair deficient (dMMR)... Read more









